TLR9 and cancer: The results obtained here reinforce the previously formulated hypothesis in dogs with DLBCL, suggesting that TLR7 and TLR9 upregulation and the concomitant p52 and IL-1R8 downregulation in B cells could lead to an exaggerated and uncontrolled inflammatory-like process that is characterized by activated B cells, eventually evolving into cancer.